ARTICLE | Clinical News

Raxone idebenone: Phase III started

October 3, 2016 7:00 AM UTC

Santhera began the double-blind, placebo-controlled, international Phase III SIDEROS trial to evaluate 300 mg oral Raxone thrice daily for 18 months in about 260 DMD patients receiving concomitant glucocorticoids. Patients who complete the trial may enroll in an open-label extension. ...